AACR Annual Meeting 2024

March 11, 2024

GemPharmatech will be attending the American Association for Cancer Research (AACR) Annual Meeting at the San Diego Convention Center from April 5ᵗʰ-10ᵗʰ, 2024! We look forward to having you visit us at Booth #3153, talk to our experts about your drug development plans, and learn more about our advanced mouse models and one-stop services for your preclinical research programs.


1710228995762028405[1].jpg


Meet with us at AACR

GemPharmatech has the world’s largest collection of genetically engineered mouse models. Understanding which of the 23,000 models is right for your project needs can be a daunting task—that is why we are making ourselves available all throughout the meeting to speak about your research and how we can help. 


MEET US


Poster Schedule:

Our 6 meeting posters include some of our most cutting-edge research. If you are unable to attend a session, you can also book a meeting here.


Sunday, April 7, 2024

1:30 PM - 5:00 PM | Section 4

Development of a novel murine model, NCG-M/hIL15, for enhanced post-HSC transplantation immunoreconstruction

Poster Board Number:22


1:30 PM - 5:00 PM | Section 22

Breaking through ADCs resistance:Constructing preclinical enhertu-induced resistant model

Poster Board Number:4


Monday, Apr 8, 2024

1:30 PM - 5:00 PM | Section 10

Development and application of the NCG-hIL2 mouse model: A humanized platform for enhanced NK cell evaluation in ADCC efficacy testing

Poster Board Number:18


Tuesday, April 9, 2024

9:00 AM - 12:30 PM | Section 9

Patient-derived xenograft (PDX) models with differential HER2 expression for preclinical evaluation of HER2-targeted therapies

Poster Board Number:14


9:00 AM - 12:30 PM | Section 9

BALB/c-hIL12RB1/hIL12RB2: A robust model for preclinical research in human IL-12 therapy

Poster Board Number:13


1:30 PM - 5:00 PM | Section 4

NeoMab: A novel platform for fully human therapeutic antibody development

Poster Board Number:13


SPEAK WITH US AT AACR →

Preclinical PD-1 Resistance Models: Crucial Tools for Unveiling PD-1 Resistance Mechanisms and Advancing Novel Treatment Strategies

Preclinical PD-1 Resistance Models: Crucial Tools for Unveiling PD-1 Resistance Mechanisms and Advancing Novel Treatment Strategies

The interaction between PD-1 and PD-L1 promotes tumor immune evasion, but immune checkpoint inhibitors can reinvigorate the immune system. However, most patients don't respond well to anti-PD-1/PD-L1 therapy, leading to acquired resistance. Establishing reliable preclinical resistance models is vital for understanding resistance mechanisms and developing new treatments.
Download